Novocure Wins FDA Approval for First Mesothelioma Treatment in 15 Years

Shares of NovoCure are up more than 6% in premarket trading after the company announced it won regulatory approval for its mesothelioma treatment, NovoTTF-100L System.Novocure, based in the U.K., said the U.S. Food and Drug Administration (FDA) approved NovoTTF-100L System in combination with pemetrexed plus platinum-based chemotherapy as a first-line treatment of unresectable, locally advanced or metastatic, malignant pleural mesothelioma. This marks the first FDA approval for malignant pleural mesothelioma (MPM) in 15 years, Novocure said in its announcement.